# Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient

> **NCT01955629** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 4 (actual)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** Aflibercept AVE0005
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01955629
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-12
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The study enrollment was prematurely halted due to safety reasons.
- **Last updated:** 2016-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01955629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01955629, "Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01955629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*